Evidence map›Paper›PMID 34359581›Full record

ReviewCancers2021

The Role of DND1 in Cancers.

Yun Zhang, Jyotsna D Godavarthi, Abie Williams-Villalobo, Shahrazad Polk, Angabin Matin

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Biochemistry and biophysics reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yun ZhangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Jyotsna D GodavarthiDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.ORCID 0000-0002-4548-9917
Abie Williams-VillaloboDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Shahrazad PolkDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Angabin MatinDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.ORCID 0000-0002-7592-3438
Texas Southern University · US

Funding

Targeted Nano-drug-delivery-systems of Frist-in-class Drugs for CRPC: PK/PD Evaluation and Combination TherapyU54MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI Dong Liang · 2020 to 2026
$22.0M
The Age-Dependence and Cell-Specificity of Breast Cancer Driven by Mutant p53SC2GM135111 · NIGMS · TEXAS SOUTHERN UNIVERSITY · PI ZHANG, YUN · 2020 to 2022
$459k
Cancer Prevention and Research Institute of Texas RP180748NIGMS NIH HHS 1SC2GM135111-01NIGMS NIH HHS SC2 GM135111NIH HHS U54MD007605
6 · The paper itself

Abstract

The

Indexed as

DND1germ cellsomatic cancersteratomastranslation regulator

Identifiers

PMID34359581
PMCPMC8345090
OpenAlexW3183267043

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.